Laurie H. Glimcher, MD, president and CEO of Dana-Farber Cancer Institute, is named to STAT's 2024 STATUS List, featuring 50 influential people shaping the future of health and life sciences across biotech, medicine, health care, policy, and health tech. Glimcher is one of eleven leaders from across the country who were selected in the category of medicine.
In naming her to this prestigious list, STAT notes, "As CEO of the Dana-Farber Cancer Institute, Laurie Glimcher isn't afraid to shake things up. She made big waves last year when the institute announced that it was ending its 30-year partnership with Brigham & Women's Hospital in favor of a deal to build a $1.6 billion cancer hospital with Beth Israel Deaconess Medical Center."
"I am honored to be recognized among this esteemed group of leaders in health science and extend my congratulations to all the talented people on this list," said Glimcher. "I am fortunate to be leading an institution with the finest cancer scientists, clinicians, nurses, and staff. We've accomplished much but there is still much to do. I look forward to continued innovation and risk-taking, aimed at helping patients at Dana-Farber and around the world."
Glimcher was named President and CEO of Dana-Farber Cancer Institute in 2016. She is also Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research.